NASDAQ:BPTH

Bio-Path Stock Forecast, Price & News

$6.48
-0.01 (-0.15 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.31
$6.48
50-Day Range
$5.13
$6.85
52-Week Range
$3.12
$24.34
Volume60,940 shs
Average Volume1.42 million shs
Market Capitalization$45.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93
30 days | 90 days | 365 days | Advanced Chart
Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.


Bio-Path logo

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.24 out of 5 stars

Medical Sector

923rd out of 2,097 stocks

Pharmaceutical Preparations Industry

448th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

Is Bio-Path a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Path?

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Bio-Path
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings results on Friday, May, 14th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.07.
View Bio-Path's earnings history
.

How has Bio-Path's stock been impacted by Coronavirus?

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BPTH shares have increased by 36.4% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19
.

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Shares of Bio-Path reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for BPTH?

2 brokerages have issued 1 year price objectives for Bio-Path's stock. Their forecasts range from $12.00 to $13.00. On average, they anticipate Bio-Path's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 92.9% from the stock's current price.
View analysts' price targets for Bio-Path
or view top-rated stocks among Wall Street analysts.

Who are Bio-Path's key executives?

Bio-Path's management team includes the following people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 72, Pay $660.17k)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 65, Pay $50.64k)
  • Mr. Anthony Price, Sr. VP of Fin., Accounting & Admin.
  • Dr. Ana Tari Ashizawa Ph.D., MBA, Sr. VP of Research, Devel. & Clinical Design
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant
  • Dr. Jeffery Lancet M.D., Consultant
  • Ms. Victoria Lake Rac, Regulatory Consultant

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.06%), Geode Capital Management LLC (0.81%), Morgan Stanley (0.57%), Citadel Advisors LLC (0.30%), Citadel Advisors LLC (0.30%) and Dimensional Fund Advisors LP (0.26%).
View institutional ownership trends for Bio-Path
.

Which major investors are selling Bio-Path stock?

BPTH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Bio-Path
or view top insider-selling stocks.

Which major investors are buying Bio-Path stock?

BPTH stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Bio-Path
or or view top insider-buying stocks.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $6.48.

How much money does Bio-Path make?

Bio-Path has a market capitalization of $45.10 million. The company earns $-10,880,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis.

How many employees does Bio-Path have?

Bio-Path employs 10 workers across the globe.

What is Bio-Path's official website?

The official website for Bio-Path is www.biopathholdings.com.

Where are Bio-Path's headquarters?

Bio-Path is headquartered at 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.